Milica Gregorič Kramberger
Dr. Milica Gregorič Kramberger is the head of the Cognitive Disorders Center at the Neurology Clinic of UKC Ljubljana. She has been in the news following the European Commission's approval of Leqembi, the first drug intended for the treatment of mild cognitive impairment in the early stages of Alzheimer's disease, with plans to initiate a pilot project for its use in patients by the end of the year.
Not in the pool (under ¢1).
Recent news mentions
Milica Gregorič Kramberger explains that lecanemab contains monoclonal antibodies aimed at the disease process of Alzheimer's.
Kaj prinašajo nova zdravila za demenco?
Slovenia· 2026-07-01
Izr. prof. dr. Milica Gregorič Kramberger emphasized the importance of quality aging and timely treatment.
Pozitivni vplivi vlaganja v zdravje in zdravstvoSlovenia· 2026-05-27
Milica Gregorič Kramberger is the head of the center for cognitive disorders at the neurology clinic in UKC Ljubljana.
Evropska komisija končno odobrila prvo zdravilo za demencoSlovenia· 2025-04-23